Intercept Pharmaceuticals Inc (ICPT): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Intercept Pharmaceuticals ( ICPT) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.7%. By the end of trading, Intercept Pharmaceuticals fell $20.06 (-5.5%) to $346.51 on light volume. Throughout the day, 546,164 shares of Intercept Pharmaceuticals exchanged hands as compared to its average daily volume of 770,200 shares. The stock ranged in price between $342.70-$373.85 after having opened the day at $367.51 as compared to the previous trading day's close of $366.57. Other companies within the Drugs industry that declined today were: Ohr Pharmaceutical ( OHRP), down 18.9%, Galena Biopharma ( GALE), down 14.3%, Tianyin Pharmaceutical ( TPI), down 13.1% and Prana Biotechnology ( PRAN), down 10.9%.

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver diseases utilizing its proprietary bile acid chemistry. Intercept Pharmaceuticals has a market cap of $7.1 billion and is part of the health care sector. Shares are up 440.3% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate Intercept Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Intercept Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income.

On the positive front, Aoxing Pharmaceutical Company ( AXN), up 15.4%, La Jolla Pharmaceutical ( LJPC), up 11.6%, Nanoviricides ( NNVC), up 10.9% and Tekmira Pharmaceuticals Corporation ( TKMR), up 8.1% , were all gainers within the drugs industry with Sanofi ( SNY) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

SAP Shares Leap After Cloud Business Prompts Full-Year Guidance Upgrade

SAP Shares Leap After Cloud Business Prompts Full-Year Guidance Upgrade

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%